What do current injectable weight loss drugs actually do?
Today's injectable weight loss medications, such as liraglutide (a GLP-1 agonist), are not single-shot solutions. They require repeated injections—daily or weekly—and you must keep taking them to maintain weight loss. A 2021 study of 169 South Korean patients taking liraglutide found that after 180 days (about 6 months), average weight loss was 7.8 kg (about 17 pounds), with 62% of patients losing at least 5% of their body weight [1]. The weight loss increased with longer treatment time, meaning the drug works, but only with ongoing use [1].
These drugs also come with real side effects. A 2024 case report described a patient who developed daily hemiplegic migraines (a severe type of migraine causing weakness on one side of the body) after starting an injectable GLP-1 agonist for weight loss; the migraines stopped only when the drug was stopped [3]. This highlights that even current injectables carry risks, especially for people with certain medical histories [3].
Is there a single-injection technology being tested?
Yes, but only in mice. A 2021 study tested a single injection of a gene therapy that makes the liver produce a protein called FGF21, which helps regulate metabolism and weight. In normal mice, this single injection led to weight loss, reduced body fat, and increased fat burning (thermogenesis) within just 2 weeks [5]. In mice fed a high-fat diet, the same injection protected them from further weight gain by boosting energy use in both brown and white fat [5].
However, this is a long way from human use. The study itself notes that the method needs further exploration in 'mouse models of disease' before any human trials [5]. Gene therapy in humans raises major safety concerns, including immune reactions and long-term side effects, which would require years of testing. The paper does not report any human data or timeline for clinical trials [5].
Why can't we just skip to human trials?
The gap between a promising mouse study and a human-approved drug is huge. The single-injection gene therapy in mice lasted at least 2 weeks, but human trials would need to prove it is safe, effective for years, and better than existing options [5]. Current injectables like liraglutide already achieve significant weight loss (average 7.8 kg over 6 months) and are approved for human use [1]. A single-shot alternative would have to match or beat that, while avoiding the side effects seen with GLP-1 drugs, such as the severe migraines reported in one patient [3].
Additionally, the marketing and hype around injectable weight loss drugs have already caused global shortages and raised ethical questions about turning weight loss into a quick fix [4]. Any new single-injection technology would face intense scrutiny over its safety, cost, and whether it truly offers a long-term solution without the need for lifestyle changes [4].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 2 from 2024 or later, 1 in Q1 journals, collectively cited 98 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 55 papers retrieved from a database of over 500 million.
Sources used in this answer
Clinical effectiveness of liraglutide on weight loss in South Koreans
In a retrospective study of 169 South Korean patients, liraglutide (a GLP-1 agonist) led to significant weight loss averaging 7.8 kg over 180 days, with 62% losing at least 5% of body weight; weight loss increased with longer treatment duration.
GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications
This review summarizes the pharmacology and clinical evidence for GLP-1 agonists in weight loss, noting they require repeated injections and have side effects, but are effective for reducing weight and improving obesity comorbidities.
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss
A case report describes a patient who developed daily hemiplegic migraines after starting an injectable GLP-1 agonist for weight loss; the migraines resolved only after stopping the drug, highlighting a serious adverse effect.
Injecting care and negotiating pleasures with weight loss pharmaceuticals
This analysis critiques the commercialization of injectable weight loss drugs, noting they are marketed as a 'shame-free' chronic disease treatment but require ongoing injections and sacrifice food pleasure, and have caused global shortages.
Liver-Specific Nonviral Gene Delivery of Fibroblast Growth Factor 21 Protein Expression in Mice Regulates Body Mass and White/Brown Fat Respiration
In mice, a single nonviral gene therapy injection delivering FGF21 to the liver induced weight loss, reduced fat, and boosted fat burning within 2 weeks, and protected against diet-induced obesity; no human data or clinical timeline is reported.